CLINICAL TRIALS PROFILE FOR TOPICORT
✉ Email this page to a colleague
All Clinical Trials for TOPICORT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02340169 ↗ | Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis | Completed | Taro Pharmaceuticals USA | Phase 4 | 2015-01-23 | The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function. The secondary objectives are to evaluate the efficacy parameters, pharmacokinetics and adverse event profile. |
| NCT02983981 ↗ | Topical Psoriasis Study for Patients Receiving Biologic Therapy | Completed | Taro Pharmaceuticals USA | Phase 4 | 2016-03-01 | A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks |
| NCT02983981 ↗ | Topical Psoriasis Study for Patients Receiving Biologic Therapy | Completed | Psoriasis Treatment Center of Central New Jersey | Phase 4 | 2016-03-01 | A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24 weeks |
| NCT02985736 ↗ | Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray | Completed | Taro Pharmaceuticals USA | Phase 4 | 2016-09-01 | A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis |
| NCT02985736 ↗ | Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray | Completed | Psoriasis Treatment Center of Central New Jersey | Phase 4 | 2016-09-01 | A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis |
| NCT03050294 ↗ | Evaluating Treatment Resistant Dermatitis TaroIIR | Completed | Wake Forest University Health Sciences | Phase 4 | 2017-02-01 | Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a significant amount of patients in most dermatological practices. Topical corticosteroid agents are often prescribed for treatment of both these conditions, especially when they are localized rather than wide spread. The development of resistance to treatment is termed tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to determine, under conditions designed to assure good adherence, whether topical 0.25% desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory skin disease defined by failure of previous topical steroid treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TOPICORT
Condition Name
Clinical Trial Locations for TOPICORT
Trials by Country
Clinical Trial Progress for TOPICORT
Clinical Trial Phase
Clinical Trial Sponsors for TOPICORT
Sponsor Name
